Highlights

• New lung-imaging collaboration expands across North America
• CT-based respiratory scans reach more hospitals and clinics
• Lung-function insights move closer to widespread adoption

A Expansive Step Forward for Advanced Lung Imaging Across North America

4DMedical (ASX:4DX) has expanded its long-running collaboration with Philips through a wider commercial arrangement designed to distribute the company’s CT-based lung-imaging platform, CT:VQ, throughout North America. This enhanced partnership introduces a structured order pathway that spans multiple periods ahead, giving the organisation increased clarity as it advances its commercial objectives. The announcement also arrives during a phase when interest in respiratory-focused innovation continues to rise across global markets, including the ASX stock market, where healthcare technology remains a key area of attention.

By reinforcing its collaboration with Philips, 4DMedical aims to take a major step in expanding the reach of CT-based respiratory diagnostics. CT:VQ is positioned to help clinicians gain deeper insight into lung function using existing CT systems already deployed across hospitals and community imaging facilities. This means the technology can extend modern respiratory imaging to regions that may not have access to complex nuclear medicine infrastructure.

The broader expansion aligns with ongoing market interest across sectors such as medical imaging, respiratory health, and even adjacent areas within diversified lists such as the ASX mining stocks, where technological advancement continues to influence operational capability across industries. Although healthcare and mining differ significantly, their shared reliance on innovation highlights how technology can transform long-standing practices.

With CT:VQ gaining momentum since receiving important regulatory clearance earlier in the year, the collaboration with Philips marks the next stage in building a long-term commercial roadmap. The agreement includes structured commitments that aim to provide clearer revenue visibility while driving broader adoption across hospital networks and imaging centres.

How the Expanded Partnership Strengthens Market Reach

A Wider Distribution Pathway Across North America

Under the expanded agreement, Philips will integrate CT:VQ into its existing product catalogue for North America. The group plans to promote the technology through its established hospital and imaging-centre network, using its local teams to guide clinical discussions, demonstration sessions, workflow education and on-site integration planning.

Dedicated sales and clinical specialists from Philips will anchor the expanded rollout, supported by a series of joint marketing initiatives. These efforts are designed to create wider awareness among hospital administrators, radiologists, pulmonologists and community clinicians who engage regularly in lung-health diagnostics.

The formal introduction of the collaboration at one of the world’s most recognised radiology events marked a high-visibility moment, signalling the intent to accelerate availability across multiple regions.

A Commercial Pathway Built for Multi-Period Planning

One of the key advantages of the expanded agreement is its structured approach to future demand. The contractual design includes milestone-based mechanisms, which help provide clearer commercial visibility for the periods ahead. The structure is intended not only to strengthen the strategic relationship but also to support sustained momentum as the organisation progresses through its planned expansion stages.

For 4DMedical, a clearer order pathway across multiple phases forms a foundation for accelerated adoption, scaled integration, and expanded clinical outreach programs. As healthcare organisations increasingly adopt digital and imaging-based diagnostic approaches, structured long-term partnerships are becoming a central part of technology deployment across the global health sector.

The broader strategy aligns with the type of commercial stability often sought by companies within diversified segments of the Australian market, including those within the ASX hundred and ASX three hundred, where predictable operational frameworks support long-term planning and capital allocation.

CT:VQ — Transforming Lung Imaging With CT-Based Analysis

Respiratory Imaging Without Nuclear Medicine Infrastructure

CT:VQ is built to generate detailed ventilation and perfusion information using routine non-contrast CT scans. This represents a distinct shift from nuclear-based ventilation-perfusion assessments, which require specialised infrastructure, radiotracers and carefully controlled workflows.

By harnessing existing CT systems, CT:VQ can help extend advanced respiratory imaging to a wider range of facilities, including those operating outside major metropolitan centres. This could bring advanced lung-function analysis closer to community healthcare environments.

The ability to use the widespread CT network across North America positions CT:VQ as a pathway for enhanced access to respiratory diagnostics. With respiratory conditions remaining a significant area of concern across public health systems, technologies that broaden access to lung-function insights can support earlier intervention and more informed clinical decision-making.

Mapping Lung Function in Greater Detail

CT:VQ produces granular maps that highlight ventilation and perfusion characteristics across various regions of the lungs. These insights can help clinicians identify abnormalities that may not always be visible through standard CT visual inspection alone.

The workflow advantage is equally noteworthy. Because CT scans are already part of routine imaging protocols in hospitals and clinics, integrating CT:VQ into existing processes offers a practical route for hospitals aiming to strengthen their respiratory diagnostic capability.

As respiratory imaging evolves into a more data-driven field, quantitative analysis from CT:VQ may help clinicians gain a deeper understanding of lung diseases, monitor progression, and assess responses to therapy with enhanced clarity.

Why the Market Is Closely Watching This Development

A Step Forward for Imaging-Technology Commercialisation

The expanded agreement between 4DMedical and Philips comes at a time when the global healthcare sector is increasingly prioritising digital imaging, quantitative data and scalable diagnostic solutions. The partnership also reflects a broader trend of global technology leaders collaborating with specialised innovators to accelerate uptake of new healthcare tools.

For investors who track innovation across the ASX dividend stocks, the healthcare sector often plays a critical role in shaping long-term growth themes. Technologies with strong clinical use-cases tend to draw consistent interest across market cycles. In this context, 4DMedical’s broadened collaboration highlights how diagnostic innovation can evolve from early-stage research toward broader commercial rollout.

A Strategic Position Within the Evolving Respiratory-Imaging Landscape

The global focus on respiratory health has strengthened over recent years, driven by sustained interest in early diagnosis, better monitoring tools, and improved hospital workflow efficiency. CT:VQ aligns with these priorities by offering practical integration, detailed functional analysis, and broad scalability.

By extending reach through Philips, 4DMedical aims to establish CT:VQ as a core component of modern lung-function evaluation. The partnership brings together established distribution capability with specialised imaging innovation.

This may mark a key moment in the transformation of respiratory imaging workflows, particularly within large-scale health systems across North America.

What This Means for Healthcare Providers Moving Forward

Healthcare organisations across the region are continuously exploring ways to enhance diagnostic capability while improving accessibility for patients. With CT:VQ able to operate through widely available CT systems, the technology could help bridge gaps between advanced imaging needs and real-world resource constraints.

From a workflow perspective, the use of routine CT scans eliminates the need for nuclear medicine scheduling, radiotracer preparation and lengthy waiting periods. This simplifies the process for both clinicians and patients.

As the partnership unfolds, hospitals may gain access to enhanced tools for diagnosing a wide range of respiratory conditions. This represents a meaningful progression in the integration of quantitative data into routine clinical practice.